Award
National Institute of Neurological Disorders and Stroke 5R33NS122096-05
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma
Recipient
Mayo Clinic Rochester
Award Amount
$397,786.00
Ceiling
$397,786.00
Awarded
March 05, 2026
Identifier
5R33NS122096-05
NIH funded project to study D-2-hydroxyglutarate as a biomarker for monitoring IDH-mutant glioma, involving feasibility, discovery, and validation phases to improve disease monitoring and therapy response assessment.
Description
This project aims to evaluate D-2-hydroxyglutarate (D2-HG) in cerebrospinal fluid (CSF) as a biomarker for monitoring IDH-mutant glioma. The study involves phased, milestone-driven feasibility, discovery, and validation analyses to determine the performance characteristics of CSF D2-HG, establish diagnostic thresholds, and validate its responsiveness to therapy and disease progression.